Janux Therapeutics (NASDAQ:JANX) Releases Earnings Results, Beats Expectations By $0.13 EPS

Janux Therapeutics (NASDAQ:JANX) announced its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13, FiscalAI reports. The firm had revenue of $9.29 million during the quarter, compared to analysts’ expectations of $8.03 million.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX traded up $0.70 during trading on Friday, hitting $16.76. 200,632 shares of the company were exchanged, compared to its average volume of 1,053,921. The firm’s 50 day moving average price is $17.52 and its 200-day moving average price is $15.39. Janux Therapeutics has a 12-month low of $12.12 and a 12-month high of $35.34. The stock has a market capitalization of $1.02 billion, a P/E ratio of -10.22 and a beta of 2.44.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on JANX shares. Barclays lifted their price objective on shares of Janux Therapeutics from $14.00 to $15.00 and gave the stock an “underweight” rating in a research note on Friday. Wolfe Research upgraded Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research note on Monday, August 24th. Stifel Nicolaus set a $35.00 price target on Janux Therapeutics in a research report on Friday, August 7th. HC Wainwright reiterated a “buy” rating on shares of Janux Therapeutics in a research note on Monday, October 19th. Finally, Guggenheim cut their price objective on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.85.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.